MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
3.490
+0.090
+2.65%
Opening 10:34 02/13 EST
OPEN
3.400
PREV CLOSE
3.400
HIGH
3.495
LOW
3.390
VOLUME
437.63K
TURNOVER
--
52 WEEK HIGH
4.175
52 WEEK LOW
0.6925
MARKET CAP
834.33M
P/E (TTM)
-6.5136
1D
5D
1M
3M
1Y
5Y
1D
Esperion Therapeutics Grants 40,200 Inducement RSUs to New Employees
Reuters · 1d ago
ESPERION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Barchart · 2d ago
Top Quant rated bullish small cap stocks among companies with high short interest
Seeking Alpha · 2d ago
Weekly Report: what happened at ESPR last week (0202-0206)?
Weekly Report · 4d ago
Bank of America Securities Remains a Sell on Esperion (ESPR)
TipRanks · 02/03 12:08
Weekly Report: what happened at ESPR last week (0126-0130)?
Weekly Report · 02/02 09:19
Weekly Report: what happened at ESPR last week (0119-0123)?
Weekly Report · 01/26 09:19
More
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.